Abstract:Background To explore the correlation between gut microbiota and disease severity in patients with primary biliary cholangitis (PBC). Methods According to the natural course of the disease, 18 PBC patients were divided into two groups: early stage (asymptomatic stage and symptomatic stage) and decompensated stage. Ten patients with decompensated hepatitis B cirrhosis, 10 patients with decompensated alcoholic cirrhosis, and 10 healthy people were selected as controls. 16sRNA sequencing was performed in the fresh feces of the research subjects. To compare the composition of gut microbiota among decompensated PBC and early-stage PBC as well as other common decompensated chronic liver disease patients. Correlation analysis was conducted with clinical indicators. Results The diversity and abundance of gut microbiota in PBC patients decreased significantly compared to the healthy control group. The composition of the gut microbiota in the early PBC group was similar to that of the healthy control group, while the composition of the gut microbiota in the decompensated PBC group was less similar to that of the healthy control group (figure 1). Upon correlating clinical indicators with gut microbiota, it was revealed that genera such as Roseburia, Agathobacter, and Ruminococcus were found to be negatively correlated with the Child-Pugh score and total bilirubin (TBIL) levels, while positively correlated with albumin levels (figure 2). Furthermore, employing LEfSe for all groups comparisons, a total of 8 potential biomarkers at the genus level were identified: Agathobacter and Fusicatenibacter in the healthy control; Ligilactobacillus and Roseburia in the early PBC group; Veillonella and Klebsiella in the decompensated PBC group; Dialister in the decompensated hepatitis B cirrhosis group; Faecalibacterium in the decompensated alcoholic cirrhosis group (figure 3). Conclusions The gut microbiota of PBC patients exhibit dysbiosis, suggesting its involvement in the pathogenesis of the disease. Gut microbiota may potentially distinguish PBC from other common decompensated chronic liver diseases. Certain specific gut microbiota may be associated with disease progression.

Rationality of medication based on the "ascending" pathophysiology of cholestatic liver disease

Consensus on the Diagnosis and Treatment of Cholestatic Liver Diseases (2015, China)

Clinical Analysis of Primary Biliary Cirrhosis: a Report of 31 Cases

Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products

New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease

The pathophysiology of cholestasis with special reference to primary biliary cirrhosis

Primary biliary cholangitis: pathogenesis and therapeutic opportunities

Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics

[The Descending Pathophysiology Model of Cholestatic Liver Disease].

Bile acid-mediated signaling in cholestatic liver diseases

Novel and emerging therapies for cholestatic liver diseases

Clinical and Pathology Analysis of Patients with Primary Biliary Cirrhosis

Novel therapeutic targets in primary biliary cirrhosis

IDDF2024-ABS-0186 Analysis of the Correlation Between Gut Microbiota and Disease Severity in Patients with Primary Biliary Cholangitis

Uncovering key molecules and immune landscape in cholestatic liver injury: implications for pathogenesis and drug therapy

Current Status of Cholestasis: Pathogenesis, Diagnosis and Treatment

Clinically significant portal hypertension in patients with primary biliary cholangitis: Clinicopathological features and prognostic value

Advances in the Treatment of Primary Biliary Cholangitis

Mechanism of Hydrophobic Bile Acid-Induced Hepatocyte Injury and Drug Discovery